statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at...

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

In this piece, we will take a look at the 13 hot stocks to invest in according to Wall Street analysts. If you want to skip our overview of the stock market and the latest news, then you can skip...

13 Hot Stocks to Invest in According to Wall Street Analysts

Elevation Oncology, Inc. (NASDAQ:ELEV  Get Free Report) saw a significant decrease in short interest in February. As of February 29th, there was short interest totalling 3,610,000 shares, a...

Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest

JMP Securities reissued their market outperform rating on shares of Elevation Oncology (NASDAQ:ELEV  Free Report) in a research report report published on Thursday, Benzinga reports. JMP...

JMP Securities Reiterates "Market Outperform" Rating for Elevation Oncology (NASDAQ:ELEV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adaptimmune Therapeutics (ADAP Research Report), Elevation Oncology...

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)

Elevation Oncology (NASDAQ:ELEV  Free Report) had its price objective lifted by Wedbush from $5.00 to $8.00 in a research note issued to investors on Thursday, Benzinga reports. They currently...

Wedbush Raises Elevation Oncology (NASDAQ:ELEV) Price Target to $8.00

Elevation Oncology, Inc. (NASDAQ:ELEV  Free Report)  Research analysts at HC Wainwright issued their Q4 2025 earnings estimates for Elevation Oncology in a research report issued to...

HC Wainwright Weighs in on Elevation Oncology, Inc.'s Q4 2025 Earnings (NASDAQ:ELEV)

Elevation Oncology (NASDAQ:ELEV  Get Free Report)s stock had its market outperform rating reissued by analysts at JMP Securities in a research report issued on Thursday...

Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by JMP Securities

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial...

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements

Elevation Oncology GAAP EPS of -$0.19

Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.

Volume	658,115.00
52-Wk High	$5.89
52-Wk Low	$0.363

ELEV Elevation Oncology Inc

About

Feed

News

Fundamentals